Drug intelligence / Profile preview

ORIL-025

Development stage: Preclinical
Lead developer: Oncology Research International
Modality: Small Molecules

Overview

**ORIL-025** is a preclinical oncology asset from Oncology Research International. It is described by the company as a **saponin-derived compound** being developed for **cancer**, although specific tumor indications and a molecular target have not been publicly disclosed. Based on the broader ORIL platform description, ORIL saponin-based compounds are intended to modify the **cellular plasma membrane** and induce **apoptosis** in cancer cells, but this mechanism has not been specifically confirmed for ORIL-025 beyond platform-level description.

Beyond the preview

Go deeper on ORIL-025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORIL-025.

Explore the full profile